Breaking News Instant updates and real-time market news.

ADMS

Adamas Pharmaceuticals

$9.19

-0.08 (-0.86%)

13:04
01/06/19
01/06
13:04
01/06/19
13:04

Adamas Pharmaceuticals expects net sales of Gocovri to be about $13.3M for Q4

Adamas Pharmaceuticals outlined key business priorities for 2019 and provided preliminary 2018 sales results for Gocovri extended release capsules. Gocovri is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy and only medication clinically proven to reduce both dyskinesia and OFF in that population. Based on preliminary unaudited financial information, the company expects net sales of Gocovri to be approximately $13.3M for Q4 that ended December 31, 2018. During Q4, Adamas fulfilled approximately 5,700 paid prescriptions of Gocovri. Preliminary full-year unaudited net sales of Gocovri are expected to be approximately $34M, with approximately 15,500 paid prescriptions filled. Adamas ended the year with approximately $211M of cash, cash equivalents, and available-for-sale securities. Key priorities for 2019 include driving adoption and clinical conviction through commercial execution and focused education about the innovation and unique benefits of Gocovri; continue to maintain excellent persistence and durable use through positive patient experience; target an approximate doubling of total prescriptions for 2019 over 2018; advance the medical literature regarding Gocovri in the Parkinson's disease treatment journey and time dependent mechanisms of disease and action by continuing to publish data at major scientific and medical meetings; completion of enrollment for the Phase 3 INROADS study of ADS-5102 extended release capsules for multiple sclerosis walking impairment in the first half of 2019 and release top-line data in the second half of 2019; continue to advance ADS-4101 towards registration studies.

ADMS Adamas Pharmaceuticals
$9.19

-0.08 (-0.86%)

11/05/18
MZHO
11/05/18
DOWNGRADE
Target $18
MZHO
Neutral
Adamas Pharmaceuticals downgraded to Neutral from Buy at Mizuho
Mizuho analyst Irina Koffler downgraded Adamas Pharmaceuticals to Neutral and lowered her price target for the shares to $18 from $75. The analyst sees increased risk for shares given the disappointing launch of Gocovri.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $40
HCWC
Buy
Adamas Pharmaceuticals 30% selloff last week unwarranted, say H.C. Wainwright
Despite reporting "evidence of healthy demand" for Gocovri and confirmation that growth of the product revenue base would be slow but steady, shares of Adamas Pharmaceuticals fell roughly 30% at the end of last week on apparent concerns over slowing expansion in the number of patients on the drug, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. In his view, however, Gocovri should continue to gain traction driven by the "twin properties" of long-term sustained efficacy benefit and the ability to significantly decrease the number of transitions experienced by Parkinson's disease patients. The analyst views last week's selloff as unwarranted and reiterates a Buy rating on Adamas Pharmaceuticals. He lowered his price target for the shares to $40 from $45.
11/12/18
LEER
11/12/18
INITIATION
Target $20
LEER
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Leerink
Leerink Partners analyst Marc Goodman started Adamas Pharmaceuticals with an Outperform rating and $20 price target.
11/13/18
LEER
11/13/18
INITIATION
Target $20
LEER
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started Adamas Pharmaceuticals with an Outperform and $20 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Adamas Pharmaceuticals, Goodman notes that Gocovri is in the early stages of growth and despite the slow launch, he believes it has potential to drive about $300M of sales in 2029 for its lead indication in the treatment of dyskinesias in Parkinson's Disease patients

TODAY'S FREE FLY STORIES

03:55
01/17/19
01/17
03:55
01/17/19
03:55
General news
FX Action: USD-CAD a posted a three-day high »

FX Action: USD-CAD a…

03:00
01/17/19
01/17
03:00
01/17/19
03:00
General news
FX Update: An abatement in risk appetite has impacted currencies »

FX Update: An abatement…

01:50
01/17/19
01/17
01:50
01/17/19
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

RVNC

Revance

$18.11

-2.11 (-10.44%)

21:05
01/16/19
01/16
21:05
01/16/19
21:05
Syndicate
Revance 5.9M share Secondary priced at $17.00 »

Goldman Sachs, Cowen and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MRTX

Mirati Therapeutics

$62.51

-2.33 (-3.59%)

20:49
01/16/19
01/16
20:49
01/16/19
20:49
Syndicate
Mirati Therapeutics 1.6M share Spot Secondary priced at $62.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

BREW

Craft Brew

$15.50

0.19 (1.24%)

20:45
01/16/19
01/16
20:45
01/16/19
20:45
Initiation
Craft Brew initiated at Maxim »

Craft Brew initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROX

Castle Brands

$0.91

0.0122 (1.36%)

20:41
01/16/19
01/16
20:41
01/16/19
20:41
Initiation
Castle Brands initiated at Maxim »

Castle Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRT

PermRock Royalty Trust

$9.61

-0.39 (-3.90%)

20:39
01/16/19
01/16
20:39
01/16/19
20:39
Downgrade
PermRock Royalty Trust rating change at Stifel »

PermRock Royalty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBCI

Glacier Bancorp

$42.87

1.36 (3.28%)

20:38
01/16/19
01/16
20:38
01/16/19
20:38
Hot Stocks
Glacier Bancorp acquires FNB Bancorp »

Glacier Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 12

    Mar

ERJ

Embraer

$22.81

-0.59 (-2.52%)

20:34
01/16/19
01/16
20:34
01/16/19
20:34
Downgrade
Embraer rating change at Morgan Stanley »

Embraer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AICAF

Air China

$0.00

(0.00%)

20:32
01/16/19
01/16
20:32
01/16/19
20:32
Upgrade
Air China rating change at HSBC »

Air China upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEA

China Eastern Airlines

$28.64

-0.09 (-0.31%)

20:26
01/16/19
01/16
20:26
01/16/19
20:26
Upgrade
China Eastern Airlines rating change at HSBC »

China Eastern Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$44.48

1.59 (3.71%)

, BBT

BB&T

$47.55

1.2 (2.59%)

20:25
01/16/19
01/16
20:25
01/16/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MS

Morgan Stanley

$44.48

1.59 (3.71%)

BBT

BB&T

$47.55

1.2 (2.59%)

PPG

PPG

$102.58

1.58 (1.56%)

MTB

M&T Bank

$154.45

3.04 (2.01%)

KEY

KeyCorp

$16.75

0.44 (2.70%)

FAST

Fastenal

$54.11

-0.47 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 11

    Feb

  • 23

    May

  • 18

    Oct

FDC

First Data

$21.27

3.72 (21.20%)

20:07
01/16/19
01/16
20:07
01/16/19
20:07
Downgrade
First Data rating change at Goldman Sachs »

First Data downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

VEON

Veon

$2.56

-0.03 (-1.16%)

19:44
01/16/19
01/16
19:44
01/16/19
19:44
Downgrade
Veon rating change at VTB Capital »

Veon downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,682.84

7.84 (0.47%)

19:22
01/16/19
01/16
19:22
01/16/19
19:22
Hot Stocks
Amazon announces AWS Backup service »

Amazon Web Service, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 28

    Jan

  • 20

    Feb

  • 03

    Mar

GS

Goldman Sachs

$197.03

17.12 (9.52%)

19:09
01/16/19
01/16
19:09
01/16/19
19:09
Periodicals
WSJ's "Heard on the Street" column says to look past Goldman Sachs Q4 glitter »

The Wall Street…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

TSLA

Tesla

$346.03

1.78 (0.52%)

18:57
01/16/19
01/16
18:57
01/16/19
18:57
Periodicals
CA makes up large portion of Tesla Model 3 registrations in 2018, Bloomberg says »

The state of California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

CARS

Cars.com

$23.14

-0.26 (-1.11%)

, MNKD

MannKind

$1.32

-0.06 (-4.35%)

18:46
01/16/19
01/16
18:46
01/16/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Cars.com (CARS)…

CARS

Cars.com

$23.14

-0.26 (-1.11%)

MNKD

MannKind

$1.32

-0.06 (-4.35%)

FOLD

Amicus

$12.18

0.19 (1.58%)

FUL

H.B. Fuller

$43.35

0.09 (0.21%)

PLXS

Plexus

$54.88

1.195 (2.23%)

CSX

CSX

$65.36

0.27 (0.41%)

KMI

Kinder Morgan

$17.46

0.15 (0.87%)

AA

Alcoa

$29.02

0.13 (0.45%)

ACB

Aurora Cannabis

$7.33

0.35 (5.01%)

MRTX

Mirati Therapeutics

$62.51

-2.33 (-3.59%)

AAPL

Apple

$154.88

1.84 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

  • 29

    Jan

  • 29

    Jan

  • 10

    Feb

  • 11

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    May

  • 17

    Jan

BAC

Bank of America

$28.44

1.89 (7.12%)

18:46
01/16/19
01/16
18:46
01/16/19
18:46
Periodicals
BofA's global investment banking head to leave bank, FT reports »

Bank of America's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 12

    Feb

  • 03

    Mar

NEWR

New Relic

$90.47

1.38 (1.55%)

18:44
01/16/19
01/16
18:44
01/16/19
18:44
Hot Stocks
New Relic CEO: 'We are an app-centric company' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 06

    Feb

  • 25

    Feb

  • 14

    Mar

TME

Tencent Music

$12.99

0.57 (4.59%)

18:33
01/16/19
01/16
18:33
01/16/19
18:33
Initiation
Tencent Music initiated at JPMorgan »

Tencent Music initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASCMA

Ascent Capital

$0.40

-0.0499 (-11.09%)

18:27
01/16/19
01/16
18:27
01/16/19
18:27
Hot Stocks
Ascent Capital announces strategic review »

Ascent Capital Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMS

CMS Energy

$50.56

0.34 (0.68%)

18:19
01/16/19
01/16
18:19
01/16/19
18:19
Initiation
CMS Energy initiated at Goldman Sachs »

CMS Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

DTE

DTE Energy

$111.73

0.48 (0.43%)

18:15
01/16/19
01/16
18:15
01/16/19
18:15
Initiation
DTE Energy initiated at Goldman Sachs »

DTE Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.